Results of a Phase II trial presented at the 2022 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer suggest that letrozole plus abemaciclib combination therapy has encouraging and durable activity in people with recurrent, estrogen receptor (ER)-positive endometrial cancer. Endometrial cancer is the sixth most common cancer worldwide…

Findings from a study in patients with colorectal cancer suggests that personalized medicine may benefit from using biomarkers based on biophysically defined subsets of mutations instead of gene-based and allele-based biomarker strategies. Some patients are not eligible for targeted treatments for colorectal cancer because they have cancer-promoting mutations that are…

A team of computational scientists at the Salk Institute for Biological Studies has combined gene mutation information with cancer prevalence data to reveal the genetic basis of cancer in the entire population of cancer patients in the United States. The study, published in Nature Communications, reveals how commonly each gene…

Over the last week, the world of cancer research, diagnostics and therapeutics has been congregating on the European Society of Medical Oncology (ESMO) website to view a wide variety of cutting-edge research presentations at the organization’s annual conference. The biggest congress in Europe with a focus on cancer research, the…

An international collaborative research effort led by scientists from Washington University, St. Louis, Baylor College of Medicine, Houston, and Johns Hopkins University, Baltimore, has taken a multi-omic approach to better understand the the elusive molecular triggers of pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive form of cancer and chances…

A large international study has identified the genetic pathways through which lung cancer occurs in people who have never smoked. The research, which is published in Nature Genetics, showed that lung cancer that arises in non-smokers has a distinct genetic signature compared with smoking-related lung cancer and largely happens due…

A new preclinical study suggests that treating people who have aggressive cancers with immune checkpoint inhibitors, quickly followed with mutation-targeted therapy, can help overcome treatment resistance, a common problem with these types of malignancies. “We already have powerful drugs in our arsenal against advanced cancers,” said co-senior author Roger S. Lo,…

Researchers at École Polytechnique Fédérale De Lausanne (EPFL) recently published their method shown to enhance immunotherapy for other cancers and apply it to lung cancer which has shown low rates of response to immune checkpoint blockade treatments. “The type of immunotherapy approved for lung cancer treatment, called immune checkpoint blockade…

Proteome-focused precision medicine drug developer Frontier Medicines announced today it closed an $88.5 million Series B financing round. The financing was co-led by Woodline Partners LP and RA Capital Management, with equal participation by Deerfield Management Company. Proceeds will be used in the development of the company’s foundational technologies of…

Cells originating from different organs are differentially susceptible to activating mutations in cancer drivers, according to a report from scientists at the German Cancer Consortium (DKTK), the Technical University of Munich (TUM), and the University Medical Center Göttingen. Their recent study showed that the same mutation in precursor cells of…

New research by scientists at Columbia University Vagelos College of Physicians and Surgeons and Herbert Irving Comprehensive Cancer Center and with collaborators at the University of Pennsylvania, demonstrates that lowering levels of the hormone PTHrP can prevent metastases and improve survival in mice with pancreatic cancer. “Pancreatic cancer metastasis is…

A team of investigators, led by scientists at Cold Spring Harbor Laboratory (CSHL) Cancer Center, have uncovered some of the underlying mechanisms that drive cancer drug resistance. While investigating the basis of “adaptive resistance” common to pancreatic cancer, the researchers discovered one of the backups to which these cells switch…

In a planned acquisition aimed at expanding its next-generation sequencing (NGS)-based capabilities in cancer diagnostics, Agilent Technologies announced yesterday it has agreed to buy Resolution Bioscience for up to $695 million. Once rolled into the company, Resolution Bioscience’s liquid biopsy platform will complement Agilent’s existing tissue-based companion diagnostics business. In…

Scientists are applying a common understanding of cancer cells—the fact that most cancer cells are aneuploid—to large-scale RNA-sequencing to better distinguish them from normal cells within a tumor. Known as CopyKAT (copy number karyotyping of aneuploid tumors), the tool serves as a computational method for detecting cancerous cells amidst large…

Resolution Bioscience announced it had entered a companion diagnostic agreement with Mirati Therapeutics. Under the agreement, Resolution will leverage its ctDx liquid biopsy platform to identify patients who may benefit from Mirati’s investigation KRAS G12C inhibitor in the treatment of non-small cell lung cancer (NSCLC). “We are excited to join…